A Phase 4 interventional study of IPV in Poliomyelitis, sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh. Status unknown at 2 sites in Bangladesh. Open to participants aged 9 Months to 13 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh · Phase 4, Interventional, and Prevention
Following a recommendation on October 2017 meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization; low- risk bOPV-using countries may adopt 2 dose fIPV schedule prior to global OPV cessation as it provides better seroconversion than 1 full dose IPV and in the post-cessation era, the 2 fIPV doses will provide sufficient (above 90%) seroconversion. Countries, which delayed the introduction of IPV or had a vaccine stock-out, should provide 1 full dose or 2 fIPV doses to all children who were missed as soon as supply becomes available. The IPV supply situation is expected to improve in 2018; all countries are expected to have access to IPV for their routine immunization programmes from the end of the first quarter of 2018.
While immunogenicity after one and two doses of IPV and fIPV has been estimated when administered to younger children ; the immunogenicity of IPV (or fIPV) when administered at 9 months of age or later is not known. We propose to conduct a study to assess the immunogenicity of one and two doses of fIPV and IPV when administered between 9-13 months of age.
222 studies on the registry are indexed under Poliomyelitis; 11 are open to participants now.
This study's planned enrollment of 300 is below the median of 456 across 199 interventional studies indexed under Poliomyelitis.
Browse Poliomyelitis studies →International Centre for Diarrhoeal Disease Research, Bangladesh is the lead sponsor of 197 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
IPV first dose between 9 -13 months with second dose administered 2 months later.
Biological: IPV
fIPV first dose between 9 -13 months with second dose administered 2 months later
Biological: IPV
The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
Also known as: fIPV
Seroconversion to PV2 two months after the first fIPV or IPV dose
Time frame: 2 months
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Centre for Diarrhoeal Disease Research, Bangladesh